anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Opioid-sparing pain management is an integral component of enhanced recovery after colonic and rectal surgery. In our hospital, rectus sheath catheters (RSCs) are routinely placed during emergency laparotomy for colorectal procedures to allow a postoperative compartmental block of the surgical site with repeated doses of bupivacaine. However, RSCs require a significant amount of clinical nursing time to maintain and 'top-up'. We present a quality improvement project in which we administered single-shot liposomal bupivacaine (LB) intraoperatively as an alternative to bolus doses of conventional bupivacaine delivered through RSCs. Having thereby reduced the demands placed on nursing time through a reduction in the use of RSCs, we sought to establish whether there was any associated change in analgesic efficacy. Patient pain scores, use of patient-controlled analgesia (PCA) and length of stay following surgery were analysed before and after the introduction of LB. No disruption in these outcomes was identified using statistical process control analysis. A direct comparison of results for patients who received LB versus those who received bolus dosing of bupivacaine via RSCs found no significant differences, with a median total PCA dose of 270 mg oral morphine equivalents (OME) for patients who received LB versus 396 mg OME for patients who had RSCs (p=0.54). The median length of stay for patients who received LB was 15.5 days versus 16 days for those who had RSCs (p=0.87). We conclude that LB represents a viable alternative to boluses of conventional bupivacaine via RSCs in promoting enhanced recovery after emergency laparotomy and look to extend its use locally.
The invention relates to the technical field of traditional Chinese medicine preparation, in particular to a traditional Chinese medicine for treating throat diseases. The invention aims to provide a traditional Chinese medicine for treating throat diseases, which aims to solve the problems in the background technology. In order to achieve the purpose, the invention provides the following technical scheme: a traditional Chinese medicine for treating throat diseases comprises the following components in parts by weight: 0.5 to 2 portions of biond magnolia flower, 1 to 3 portions of wrinkled gianthyssop herb, 1 to 3 portions of burdock, 0.2 to 1 portion of dahurian angelica root, 0.2 to 1 portion of liquoric root, 0.5 to 2 portions of mint and 0.5 to 2 portions of rhubarb. The supporting spray can be used for healing within 7-15 days generally, and has the advantages of quick response, good curative effect and no toxic or side effect. Wherein, the weight ratio of flos magnoliae, wrinkled gianthyssop herb, burdock, angelica dahurica, liquorice, mint and rhubarb is 1: 2: 2: 0.5: 0.5: 1: 1, the prepared traditional Chinese medicine composition has the best curative effect, and is obviously superior to the curative effect of other components in proportion. Especially has obvious curative effect on rhinitis, pharyngitis, cold, tracheitis and asthma.
Embodiments are directed to compositions and methods for treating parasitic infections. Compounds have been identified from a library of anti-cancer drugs that serve as suitable agents for targeting trypanosomatids. Certain embodiments are directed to methods of treating eukaryotic parasites comprising administering an effective amount of a derivative. In certain embodiments the parasite is Leishmania major or Trypanosoma cruzi. Other embodiments of the invention are discussed throughout this application. Any embodiment discussed with respect to one aspect of the invention applies to other aspects of the invention as well and vice versa.
Cognitive Rehabilitation for mild brain injury has shown some modest evidence of effectiveness. CR interventions for mTBI typically focus on compensating for subjective and functional cognitive complaints. A number of recent studies have examined the use of compensatory CR approaches for individuals (primarily military veterans) diagnosed with mild cognitive impairment from a likely mTBI. These interventions taught individuals adaptive functional skills (e.g., cognitive mnemonics) and highlighted use of external aids such as smart phone scheduling/reminder applications. A randomized control trial that included 16 veterans with TBI (mixed mild and moderate severity), found this compensatory CR intervention was effective at reducing overall symptoms, but did not impact cognitive performance or work-outcomes. In a secondary study, there was some evidence that the compensatory CR intervention improved memory at 6 months post-treatment and quality of life at 12 months but there was not a consistent pattern of improvement compared to controls.

Generalizability from civilian and veteran communities to active duty SMs may pose some unique and unexplored factors as the goal of treatment is not remediation of common activities of daily living (e.g., remembering appointments) but in contrast, the goal is military readiness needed for worldwide deployability to potential wartime environments (e.g., "cognitive readiness").
PURPOSE: The objective of this study was to investigate the experience of first- and second- generation immigrant youth living with chronic health conditions in Canada, their parents or caregivers, and healthcare and service providers who care for immigrant youth, regarding the transition from pediatric to adult healthcare.
DESIGN AND METHODS: We conducted semi-structured individual interviews and focus groups. Youth were 1st or 2nd generation immigrants, aged 16-25, with pediatric-onset chronic health conditions. Parents or caregivers had raised youth children as described. Providers delivered healthcare or other services to immigrant populations. Thematic analysis was conducted of all transcripts.
RESULTS: Twenty youth, 14 parents/caregivers and five service providers participated. Most participants described healthcare transition as very difficult to navigate. Two major themes emerged across participant narratives: 1. Barriers to transition: lack of family experience in Canada, language, discrimination, financial strain, stigma, and long wait times. Some of these barriers are specific to newcomer families, but others are generalizable to the Canadian population. 2. Facilitators of transition: youth independence, youth acting as cultural bridges within their families, and cross-sector support between healthcare, education, social work and settlement services.
CONCLUSIONS: Immigrant youth and their families face a broad range of barriers to healthcare transition. The collaborative nature of cross-sector support effectively addressed some of the barriers faced by newcomer families.
PRACTICE IMPLICATIONS: Clinicians should provide immigrant youth and their families with accessible information about the health condition and how to navigate the adult healthcare system prior to transition, particularly when language barriers exist.
A 3-6-month anticoagulation therapy with warfarin is recommended after the BPV surgery. Patients allocated to the warfarin group will adhere to a target INR range of 2 to 3. Patients 65 \> years old and low weight should take warfarin 2.5mg/day and all other patients should take 5mg/day. During hospitalization, the INR will be reassessed daily, and regular measurements (at least every four weeks) should be conducted post-discharge to ensure ongoing patient stability.
Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
PURPOSE:To obtain the subject ink excellent in printability, etc., within a short time by dissolving a shellac in an alcoholic organic solvent, adding a colorant, etc., to the solution to obtain an ink and aging this ink in the presence of a cation exchange resin. CONSTITUTION:A shellac such as white shellac, purified shellac or partially esterified shellac is dissolved in an alcoholic organic solvent (e.g. ethanol) to produce a printing ink vehicle for orally a dministrable products. This vehicle or a printing ink prepared by adding additives, such as a colorant and a pigment, to this vehicle is aged in the presence of a cation exchange resin to produce the abjective ink. Thus, the aging time can be markedly shortened, and a printing ink of stable quality can be prepared within a short time. The use of this ink enables stains adherent to a transfer roller to be easily wiped away.
Cardiovascular Thrombotic Events

  * Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. [See WARNINGS and PRECAUTIONS].
  * Ibuprofen tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see CONTRAINDICATIONS and WARNINGS].



Gastrointestinal Risk

  * NSAIDS cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. [See WARNINGS].
The present invention relates to a nonspecific immune booster composition, a manufacturing method thereof, and a use thereof. The composition of the present invention, based on 100 parts by weight of potassium carbonate, is composed of: 150 to 300 parts by weight of sodium silicate; 2 to 8 parts by weight of sodium thiosulfate; 2 to 8 parts by weight of sodium chloride; 0.5 to 2 parts by weight of sodium carbonate; 0.5 to 2 parts by weight of potassium chloride; 200 to 400 parts by weight of refined sugar; and 300 to 400 parts by weight of water. The nonspecific immune booster composition as described above of the present invention may effectively defend a death rate about AIV H5N1, highly pathogenic avian influenza, improve a survival rate. When the composition is added and used in mixed feed for farm-raised fish, such as flatfish, shrimp, and etc., a group death rate of fish may be reduced so that the productivity may be improved due to the excellent nonspecific immune booster and the effect of resistance to diseases. Particularly, when the composition is applied to defend highly pathogenic malignant virus diseases and to improve the resistance to diseases for the farm-raised fish, the composition may be capable of defending against diseases and effectively prevent infection due to the immune booster effect as being the nonspecific immune booster composition. In addition, the composition has an excellent bactericidal effect against gram positive bacteria and gram negative bacteria, such as S. aureus(MRSA), E. coli, S. typhimurium, Streptococcus iniae, and Vibrio harveyi, which are multidrug resistant bacteria. Index Terms: immune booster, foot-and-mouth disease (FMD), bird flu, death rate, potassium carbonate, farm-raised fish.
Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.
Subjects will receive Prolastin, two intravenous infusion (IV) doses of 120 milligram per kilogram (mg/kg), based upon the subject's body weight, on Day 1 and Day 8. Subjects will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
Numerous primary and secondary studies have consistently demonstrated that probiotics, including lactobacillus and Bifidobacterium, possess a potential anti-obesity effect. However, it is worth noting that some studies have yielded contrasting results. Considering this, our study aims to present a comprehensive overview of published systematic reviews and meta-analyses, focusing on the efficacy and safety of probiotics in managing obesity. To achieve this objective, we conducted an umbrella review following the PRISMA protocol and Cochrane guidelines. We searched databases such as Embase, PubMed, Cochrane Library, and Google Scholar for relevant systematic reviews and meta-analyses published in English, without imposing any date restrictions. Our inclusion criteria encompassed studies evaluating the anti-obesity impact of probiotics, with a specific focus on changes in body mass index (BMI), fat mass percentage (FMP), body weight (BW), and body fat mass (BFM). These studies were meticulously reviewed by two independent reviewers. Our analysis included five systematic reviews and 18 meta-analyses that met the predefined inclusion and exclusion criteria. The meta-analyses revealed statistically significant reductions in the following parameters: BMI, a decrease of 0.30 kg/m2 (p < 0.00001, 95% CI - 0.36 to - 0.25); BFM, a reduction of 0.86 kg (p < 0.00001, 95% CI - 1.02 to - 0.71); BW, a decrease of 0.59 kg (p < 0.00001, 95% CI - 0.74 to - 0.44); and FMP, a substantial decline of 78% (p < 0.00001, 95% CI - 1.02 to - 0.54). In summary, our umbrella review suggests that existing evidence supports the potential benefits of probiotics in managing obesity and overweight. However, it is essential to acknowledge that the credibility of this evidence is somewhat limited due to the inclusion of studies with poor-quality designs and relatively small participant numbers. To establish the true efficacy of probiotics in obesity management, we recommend conducting robust studies involving larger participant cohorts.
The invention discloses a compound of a heat shock protein 70 functional peptide and an alpha fetoprotein epitope peptide. The compound is formed by coupling the heat shock protein 70 functional peptide and the alpha fetoprotein epitope peptide. The amino acid sequence of the compound is shown in SEQ ID NO.1. The mole ratio of the heat shock protein 70 functional peptide to the alpha fetoprotein epitope peptide is 1: 1. The amino acid sequence of the heat shock protein 70 functional peptide is shown in SEQ ID NO.1. The amino acid sequence of the alpha fetoprotein epitope peptide is shown in SEQ ID NO.2. According to the compound, the synthetic operation is easy, the cost is low, the resultant quantity is large, the reaction is rapid, products are relatively stable, and the novel technical content is provided for anti-tumor immunization.
The present invention provides novel methods of producing chitosan having a tap density of at least about 0.4 g/ml. In one aspect of the present invention, chitosan is selected having an average molecular mass of from about one thousand Daltons to about two million Daltons; a particle size that is smaller than 20 mesh; a viscosity of at least about 1 cps, and a percentage of deacetylation of from about 65% to about 98% A measured amount of the selected chitosan is then mixed with an amount of water that is from about two to about ten times the weight of the chitosan, and an amount of an acid that is at least about 0.1% of the weight of the chitosan. The acid is preferably an organic acid. The mixture of chitosan, water and acid is then mixed to a smooth paste, dried to a moisture content of from 0% moisture to about 20% moisture, and the particle size is preferably reduced to smaller than 20 mesh. In another aspect of the invention, chitosan is provided having a tap density of at least about 0.4 g/ml and the ability to freely flow through an orifice having a circular cross section having a diameter of about 4 mm. The chitosan of the present invention is relatively odorless.
PURPOSE:An oral administration pharmaceutical, containing ubidecarenone in a fat emulsion, having good absorbability in digestive tracts, capable of keeping a high concentration in blood, effective for improving various symptoms caused by cardiac failure, and useful as a cardiovascular pharmaceutical. CONSTITUTION:An oral administration pharmaceutical obtained by incorporating given amounts of a hydrophobic substance, e.g. vegetable oil or animal oil, with an emulsifying agent, e.g. phospholipid or nonionic surfactant, ubidecarenone and another additive, adding a required amount of water thereto, roughly emulsifying resultant mixture, and homogenizing the emulsion in an injection type high- pressure homogenizer, etc. The content of the ubidecarenone to be used is preferably 0.01-30mg/ml, particularly 0.05-20mg/ml. Administration in a high dose is not required, and development of side effects, e.g. uncomfortable feeling in the stomach part, inappetence, vomiting and diarshea, is prevented.
It is intended to provide compositions whereby oxidative stress caused by active oxygen species, free radicals, etc. in vivo can be lessened to thereby prevent the outbreak or worsening of diseases and yet a high safety can be achieved. It is observed that, by using compositions containing oxidation-type coenzyme Q and/or reduction-type coenzyme Q, urinary 8-hydroxydeoxyguanosine level is lowered in normal and diabetic animals. Also, it is histopathologically confirmed that tissue denaturation caused by oxidative stress can be prevented thereby in diabetic rats. Thus, it is found out that oxidative stress in vivo can be lessened. That is to say, oxidative stress in vivo can be lessened by using compositions containing coenzyme Q as the active ingredient.
Incretinomimetics include exogenous Glucagon-Like Peptide analogs (GLP1a) such as Liraglutide, and inhibitors of Dipeptidyl peptidase IV (DPP4i) that prolong the half-life of endogenous GLP1 such as Vildagliptin. It remains unclear which of the two strategies (exogenous GLP1 or prolonging half-life of endogenous GLP1) have better short term effect on insulin sensitivity and insulin secretion in people living with type 2 diabetes.

This study aims to investigate the short-term metabolic effects of a GLP-1 analog Liraglutide versus a DPP4i Vildagliptin. It is a randomized, controlled, single-blinded clinical trial. Study population consists of uncontrolled type 2 diabetes mellitus patients (HbA1c≥7%) under mono or bi oral anti-diabetic therapy, naïve of any incretinomimetic treatment. Participants are randomized in 2 arms. The intervention in arm 1 consists of add-on subcutaneous Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week. In the second arm, it consists of oral Vildagliptine at 100mg daily for two weeks. The primary outcome is the variation in euglycaemic hyperinsulinaemic clamp-derived insulin sensitivity before randomization and the day after intervention, secondary outcomes include 14-day changes in insulin secretion during a mixed meal tolarance test, body weight and body composition, and an indirect calorimetry measured resting energy expenditure. Changes from baseline to 14 days in serum creatinine and alanine amino transferase, C-reactive protein and lipid profile will also be recorded.
Traumatic brain injury (TBI) is a leading cause of disability and increases the risk of developing neurodegenerative diseases. The mechanisms linking TBI to neurodegeneration remain to be defined. It has been proposed that the induction of cellular senescence after injury could amplify neuroinflammation and induce long-term tissue changes. The induction of a senescence response post-injury in the immature brain has yet to be characterised. We carried out two types of brain injury in juvenile CD1 mice: invasive TBI using controlled cortical impact (CCI) and repetitive mild TBI (rmTBI) using weight drop injury. The analysis of senescence-related signals showed an increase in γH2AX-53BP1 nuclear foci, p53, p19ARF, and p16INK4a expression in the CCI group, 5 days post-injury (dpi). At 35 days, the difference was no longer statistically significant. Gene expression showed the activation of different senescence pathways in the ipsilateral and contralateral hemispheres in the injured mice. CCI-injured mice showed a neuroinflammatory early phase after injury (increased Iba1 and GFAP expression), which persisted for GFAP. After CCI, there was an increase at 5 days in p16INK4, whereas in rmTBI, a significant increase was seen at 35 dpi. Both injuries caused a decrease in p21 at 35 dpi. In rmTBI, other markers showed no significant change. The PCR array data predicted the activation of pathways connected to senescence after rmTBI. These results indicate the induction of a complex cellular senescence and glial reaction in the immature mouse brain, with clear differences between an invasive brain injury and a repetitive mild injury.
Treated Brassica seeds and their extracts for use as a flavor and/or a flavor modifier in consumables. Treatment includes heating, and optionally grinding methods and/or recovery methods. Consumables include foods, beverages, health-care products, oral hygiene and oral care products, beauty-care products, and tobacco products. The extract contains elevated amounts of flavor and flavor modifier. One flavor modifier of the extract may be 2-furfurylthiol (FFT). A process for producing treated Brassica seeds extract.
With the average-dose method, the dose was individualized according to the severity of anterior gingival exposure pretreatment. For mild gingival smile (3-5 mm), a single-site injection of 2 U botulinum toxin type A \[total, 4 U\] at both the right and left levator labii superioris alaeque nasi muscles) was administered. For moderate (5-7 mm) and severe (≥7 mm) gingival smile, 3 U and 5 U of botulinum toxin type A, respectively, were injected per side (total, 6 U and 10U, respectively). The injection points were located at bilateral levator labii superioris alaeque nasi muscles and at the Yonsei point26, with half doses administered at each point.
Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as renal impairment (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating diseases may increase the possibility of peripheral neuropathy (see WARNINGS).

Asthenia, vertigo, nystagmus, dizziness, headache, and drowsiness also have been reported with the use of nitrofurantoin.

Benign intracranial hypertension (pseudotumor cerebri), confusion, depression, optic neuritis, and psychotic reactions have been reported rarely. Bulging fontanels, as a sign of benign intracranial hypertension in infants, have been reported rarely.